Landogrozumab (INN; development code LY2495655) is a humanized monoclonal antibody and experimental pharmaceutical drug designed for the treatment of muscle wasting disorders.Statement On A Nonproprietary Name Adopted By The USAN Council - Landogrozumab, American Medical Association.
The drug was developed by Eli Lilly and Company.
References